Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastomas sensitive to cisplatin. Satoshi Nakata , Junko Murai , Masayasu Okada , Haruhiko Takahashi , Tyler H Findlay , Kristen Malebranche , Akhila Parthasarathy , Satoshi Miyashita , Ramil Gabdulkhaev , Ilan Benkimoun , Sabine Druillennec , Sara Chabi , Eleanor Hawkins , Hiroaki Miyahara , Kensuke Tateishi , Shinji Yamashita , Shiori Yamada , Taiki Saito , Jotaro On , Jun Watanabe , Yoshihiro Tsukamoto , Junichi Yoshimura , Makoto Oishi , Toshimichi Nakano , Masaru Imamura , Chihaya Imai , Tetsuya Yamamoto , Hideo Takeshima , Atsuo T Sasaki , Fausto J Rodriguez , Sumihito Nobusawa , Pascale Varlet , Celio Pouponnot , Satoru Osuka , Yves Pommier , Akiyoshi Kakita , Yukihiko Fujii , Eric H Raabe , Charles G Eberhart , Manabu Natsumeda Neuro-oncology（2022）
摘要
High SLFN11 expression is one factor which renders favorable outcomes in WNT-activated and a subset of SHH-activated medulloblastoma possibly through enhancing response to cisplatin.
更多 查看译文
关键词
DNA damaging agent, SLFN11, medulloblastoma
AI 理解论文
溯源树
样例
